眼部炎症性疾病：分子发病机制与免疫疗法

Title:Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy

Volume: 15 Issue: 6

Author(s): 眼部炎症性疾病：分子发病机制与免疫疗法

Affiliation:

关键词: B细胞治疗，细胞因子IL-12，IL-35表达的Breg细胞（i35 Breg），白细胞介素35（IL-35），调节性B细胞（Breg），细胞因子治疗，葡萄膜炎。

摘要: Uveitis is a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology and accounts for more than 10% of severe visual handicaps in the United States. Pathology derives from the presence of inflammatory cells in the optical axis and sustained production of cytotoxic cytokines and other immuneregulatory proteins in the eye. The main therapeutic goals are to down-regulate the immune response, preserve the integrity of the ocular architecture and eventually eliminate the inciting uveitogenic stimuli. Current therapy is based on topical or systemic corticosteroid with or without second line agents and serious adverse effects of these drugs are the impetus for development of less toxic and more specific therapies for uveitis. This review summarizes the pathophysiology of uveitis, molecular mechanisms that regulate the initiation and progression of uveitis and concludes with emerging strategies for the treatment of this group of potentially blinding diseases.

Cite this article as:

眼部炎症性疾病：分子发病机制与免疫疗法 , Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy, Current Molecular Medicine 2015; 15 (6) . https://dx.doi.org/10.2174/1566524015666150731095426